#VP26: The Staying Safe Intervention: Contextualizing Knowledge On HCV Transmission, Prevention, And Risk Behaviors Among YPWID

Speaker: Ramona Almeñana, CUNY School Of Public Health And Health Policy, USA

#VP27: Viral Hepatitis And HIV Education In A USA Prison System

Speaker: Mandy Altman, National Hepatitis Corrections Network, USA

#VP28: Examining Opt-In Versus Routine Opt-Out HIV/HCV Testing At A Syringe Services Program: An Interrupted Time Series Analysis

Speaker: Tyler Bartholomew, University of Miami, USA

#VP29: A Guide To Scale-Up Of Testing And Treatment For Hepatitis C In The Prison Setting: The Stop-C Implementation Toolkit

Speaker: Marianne Byrne, The Kirby Institute, UNSW Sydney, Australia

#VP30: Retrospective Review Of The TrueNorth Medical Centres Database In Canada: Assessment Of The Impact Of Simplified Care On Direct-Acting Antivirals Treatment For Hepatitis C Virus Patients In Addiction Care – Northern-HCV

Speaker: Chris Cavacuiti, TrueNorth Addiction Medicine Program, Canada

#VP31: Assessing Molecular Point-Of-Care Testing And Dried Blood Spot For Hepatitis C Virus Screening In People Who Inject Drugs: A Pilot Study

Speaker: Stephane Chevaliez, Henri Mondor Hospital, France

#VP32: Treatment Uptake For Hepatitis C Infection Following An Intervention To Enhance Linkage To Care Among People Who Inject Drugs: The Ethos Engage Study

Speaker: Anna Conway, The Kirby Institute, UNSW Sydney, Australia

#VP33: Achieving Hepatitis C Virus (HCV) Elimination In Prisons Through ‘HCV Intensive Test And Treat’ (HITT) Interventions

Speaker: Sean Cox, Hepatitis C Trust, UK

#VP34: Early Hepatitis C Virus Antibody Testing Among Recipients Of Medication For Opioid Use Disorder, Victoria, Australia, 2012 To 2020

Speaker: Joshua Dawe, Burnet Institute, Australia

#VP35: Hepatitis C Virus Cascade Of Care Among People Who Inject Drugs In Australia: Factors Associated With Testing And Treatment In A Universal Healthcare System

Speaker: Daisy Gibbs, National Drug and Alcohol Research Centre, Australia

#VP36: A Mixed-Methods Systematic Review Of Barriers And Enablers To Hepatitis C Care Among People Who Inject Drugs

Speaker: Jack Gunn, Burnet Institute, Australia

#VP37: Conceptualising Hepatitis C Stigma: A Thematic Synthesis Of Qualitative Research

Speaker: Danielle Guy, Barcelona Institute for Global Health Hospital Clinic – University of Barcelona, Spain

#VP39: Patient Perceptions Of Acceptability Of Hepatitis C Point-Of-Care Testing At A Reception Prison

Speaker: Lise Lafferty, Centre For Social Research In Health, UNSW Sydney, Australia

#VP40: Using Historic Notification Data To Increase Access To The Hepatitis C Cure: Key Stakeholder Perspectives

Speaker: Ned Latham, Burnet Institute, Australia

#VP41: Acceptability Of Community-Based Hepatitis C Testing And Treatment Among People Who Inject Drugs In Yangon, Myanmar

Speaker: Win Lei, Burnet Institute, Australia

#VP42: Willingness Among Clients To Participate In A Randomised Controlled Trial Involving Financial Incentives To Initiate Hepatitis C Treatment – A Pilot Study 

Speaker: Alison Marshall, The Kirby Institute, UNSW Sydney, Australia

#VP43: PROMPt – Point Of Care Testing For Hepatitis C In The Priority Settings Of Mental Health, Prisons And Drug & Alcohol Facilities

Speaker: Lucy Ralton, Royal Adelaide Hospital, Australia

#VP44: Opportunistic Treatment Of Hepatitis C Virus Infection (Opportuni-C): Study Protocol For A Pragmatic Stepped Wedge Cluster Randomized Trial Of Immediate Versus Outpatient Treatment Initiation Among Hospitalized People Who Inject Drugs

Speaker: Havard Midgard, Akershus University Hospital, Norway

#VP45: Partnering Peer Specialists With Nurses To Expand Access To Hepatitis C Care For People Who Inject Drugs: The Path-Expanded Evaluation

Speaker: Daniel O’Keefe, Burnet Institute, Australia

#VP46: Interventions To Improve The Uptake Of Direct-Acting Antivirals In High- And Middle-Income Countries: A Systematic Review

Speaker: David Ortiz-Paredes, Research Institute of The Mcgill University Health Centre, Canada

#VP47: Improving Complete Screening For Hepatitis C Vertical Transmission In The Perinatal Period

Speaker: Emily Ower, Vancouver Coastal Health, Canada

#VP48: The HCV Drug Policy Similarity Score Among Countries In The EU/EEA, And The UK

Speaker: Adam Palayew, University of Washington, USA

#VP49: More Intensive HCV-Care Promotes Adherence Among People Who Inject Drugs With Recent Drug Use

Speaker: Irene Pericot-Valverde, Clemson University, USA

#VP51: HCV Cascade Of Care Of People Admitted To Drug Treatment (2015-2019) In Catalonia 

Speaker: Juliana Reyes-urueña, Centre d’Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Spain

#VP52: Interventions To Increase Linkage To Care And Adherence To Treatment For Hepatitis C Among People Who Inject Drugs : A Systematic Review

Speaker: Tanja Schwarz, Austrian National Public Health Institute (gesundheit Österreich GMBH), Austria

#VP53: A Modelling Analysis Of Financial Incentives For Hepatitis C Testing And Treatment Uptake Delivered Through A Community-Based Testing Campaign

Speaker: Nick Scott, Burnet Institute, Australia

#VP54: Evaluation Of A Novel Reflexive Laboratory Bundle Combining Screening And Workup In A Hepatitis C Elimination Program 

Speaker: Andrew Seaman, Oregon Health & Science University, USA

#VP55: Blood Borne Infection And Peer Educator Training: Adapting Materials To Deliver Coursework During An Evolving Pandemic 

Speaker: Mandy Altman, National Hepatitis Corrections Network, Hepatitis Education Project, USA

#VP56: Opportunity For Targeted Hepatitis C Health Messaging For Sub-Populations Of People Who Inject Drugs In Melbourne: A Latent Class Analysis 

Speaker: Ashleigh Stewart, Burnet Institute, Australia

#VP57: Cascade Of HCV Care Among People Who Inject Drugs In Athens, Greece: Aristotle HCV-HIV Programme

Speaker: Vana Sypsa, University of Athens, Greece

#VP58: Differences In The Hepatitis C Virus Cascade Of Care And Time To Initiation Of HCV Therapy Among Vulnerable Subpopulations Using A Mobile Unit As The Point-Of-Care

Speaker: Jorge Valencia, Hospital Universitario Infanta Leonor, Spain

#VP138: Lessons Learned In Alabama’s HCV Work With The PWID Population

Speaker: Anthony Lee, UAB School of Medicine, Division of Infectious Diseases, USA

#VP139: Cedar Project HCV Blanket Program: Exploring Experiences And Impact Of A Culturally-Safe Case Management Approach In Supporting HCV Treatment Among Indigenous People Use(d) Drugs In British Columbia, Canada

Speaker: April Mazzuca, UBC School of Population and Public Health, Canada

#VP140: Cost-Effectiveness Of Pharmacy-led Versus Conventionally Delivered Antiviral Treatment for Hepatitis C In Patients Receiving Opioid Substitution Therapy: An Economic Evaluation Alongside A Pragmatic Cluster Randomised Trial

Speaker: Gareth Myring, UBC School of Population and Public Health, Canada

#PO20: Electronic Health Engagement Improves Hepatitis C Care Cascade In PWID

Speaker: Arisha Baig, Austin Hepatitis Center, USA

#PO21: Hepatitis C Cascade Of Care (CoC) For PWID Under Opiate Substitution Treatment (OST) In Greece

Speaker: Olga Anagnostou, Okana, Greece

#PO22: Factors Associated With HCV Testing In People Who Inject Drugs In France: Results From The PREBUPIV Study

Speaker: Ilhame Anwar, Inserm Sesstim, France

#PO23: Integrating All Modalities Of Hepatitis C Testing Into A Comprehensive Model For The NSW Correctional System

Speaker: Marian Bloomfield, Justice Health and Forensic Mental Health Network, Australia

#PO24: HCV Knowledge And Awareness Among Injecting Drug Users In The Direct Acting Antivirals Era

Speaker: Antonio Boschini, San Patrignano Therapeutic Community, Italy

#PO25: Cluster RCT Evaluating An Educational Program To Improve Hepatitis C Virus (HCV) Management 

Speaker: Kendal Chidwick, NPS Medicinewise, Australia

#PO26: Needs And Challenges Of Quebec Community Organizations Working With Hepatitis C And Located Outside Of The Montreal Area

Speaker: Romane Close, Centre Associatif Polyvalent D’Aide Hépatite C (CAPAHC), Canada

#PO27: HCV Contact Tracing To Engage Hard To Reach Networks: Findings From The ‘Source Patient Identification And Group Overlap Treatment’ (Spigot) Pilot Program

Speaker: Benjamin Eckhardt, NYU School of Medicine, USA

#PO28: A Causal Analysis Of The Effect Of Routine Abdominal Imaging On Risk Of Hepatocellular Carcinoma For People Living With Chronic Hepatitis C

Speaker: Shelley Facente, Facente Consulting, USA

#PO29: Benefits Of Working With A Collective Impact Initiative To Inform Research: Developing Paths To Hepatitis C Elimination For Young Adults Who Inject Drugs

Speaker: Shelley Facente, Facente Consulting, USA

#PO30: Factors Influencing The Equitable Scale-Up Of Direct-Acting Antiviral Hepatitis C Virus Treatment Among People Who Inject Drugs: A Qualitative Study In British Columbia, Canada

Speaker: Trevor Goodyear, British Columbia Centre on Substance Use, Canada

#PO31: Barriers And Facilitators Affecting Uptake Of Hepatitis C Treatment Amongst Patients On Methadone In Greater Western Sydney

Speaker: Kevin Jia, Bankstown-Lidcombe Hospital, Australia

#PO32: A Qualitative Study Investigating The Lived Experience Of Hepatitis C Diagnosis, Treatment And Cure In People Who Inject Drugs On Direct Acting Antiviral Treatment

Speaker: Amy Malaguti, University of Dundee, UK

#PO33: Ensuring Appropriate Follow-Up And Access To Screening For People At Ongoing Risk For HCV Re-Infection Post-Clearance; A Neglected Step In The HCV Cascade Of Care

Speaker: Stefanie Materniak, Centre for Research, Education and Clinical Care of At-Risk Populations (RECAP), Horizon Health Network, Canada

#PO34: Community Based Peer Facilitated Hepatitis C Point Of Care Testing Project Dublin

Speaker: Tina McHugh, Infectious Diseases Mater Hospital, UK

#PO35: Insider’s News: Peer Magazine Is A Hep C Game Changer For NSW Jails

Speaker: Leah McLeod, NSW Users & AIDS Association, Australia

#PO36: Point-Of-Care Screening Combined With Nursing And Peer-Based Outreach Work To Enhance Testing And Treatment For Hepatitis C Among People Who Use Drugs, People Who Experience Homelessness, And Migrants: The Reach_U Project

Speaker: Cristiana Merendeiro, CRESCER, Portugal

#PO37: Improving HCV Screening Adherence In An Excluded Population

Speaker: Paulo Caldeira, Ares Do Pinhal, Portugal

#PO38: Improving Access To HCV Therapy In HMP Swansea Using A Novel Point Of Care Testing Strategy And An Accelerated Pathway To Treatment

Speaker: James Plant, Swansea Bay University Health Board, UK

#PO39: Can The Online Shopping Model ‘Lock-Box Delivery’ Improve Hepatitis C Treatment Access Amongst Vulnerable Adults? 

Speaker: Fiona Rees, University Hospitals Sussex NHS Foundation Trust, UK

#PO40: Non-Clinical Service Provision Of HIV And Hepatitis C Dried Blood Spot Testing In Community Settings

Speaker: Ana Romero, HIV and Related Programs Unit, Australia

#PO41: A Novel Hepatitis C “Treatment-Ready” Self-Collect Panel: HIV, Hepatitis B Surface Antigen, Hepatitis B Core Antibody, And Hepatitis C RNA On Dried Blood Spot And Serum Separating Cards

Speaker: Andrew Seaman, Oregon Health & Science University, USA

#PO42: From Treatment Initiation To Cure: Movement Along The HCV Care Cascade Among Homeless And Unstably Housed Individuals Who Inject Drugs

Speaker: Leah Shaw, Boston Healthcare for the Homeless Program, USA

#PO43: Improving Public Health Literacy With Sector-Wide Hepatitis C Education In Australian Prisons

Speaker: Yumi Sheehan, The Kirby Institute, UNSW Sydney, Australia

#PO44: Point Of Care HCV RNA Testing In A Mobile Low-Threshold Health Service For People Who Inject Drugs

Speaker: Gunnar Thingnes, Sykepleie på hjul, Fransiskushjelpen, Norway

#PO102: Risk Perception About Hepatitis C In Psychoactive Substances Users

Speaker: Joao Curto, Dicad Coimbra, Portugal

#PO103: The Relationship Between Buprenorphine Maintenance Therapy And Incident Hepatitis C Virus Infection: A Scoping Review

Speaker: Daniel Brook, Ohio State University, USA

#VP59: HCV Phylogenetic Networks Among People Who Inject Drugs In Kenya

Speaker: Matthew Akiyama, INHSU Prisons SIG, USA

#VP60: Methods And Indicators To Validate Country Responses For Decreasing Incidence Of Hepatitis C Virus Infection To Elimination Levels Set By The World Health Organization

Speaker: Adelina Artenie, University of Bristol, UK

#VP61: HCV Treatment Uptake Among Marginalized People Who Inject Drugs In Norway: A Registry-Based Study

Speaker: Kristian Braathen Malme, Akershus University Hospital, Norway

#VP62: Health-Economic Evaluation Of A Fast-Track Hepatitis C Micro-Elimination Program Among People Who Inject Drugs Receiving Ost In The Hellenic Organization Against Drugs (Tityus Program)

Speaker: Illias Gountas, University of Athens, Greece

#VP63: Hepatitis C Testing And Treatment Among People Who Inject Drugs In Toronto, Canada

Speaker: Zoe Greenwald, University of Toronto, Canada

#VP64: The Hepris Study – Prevalence Of Hepatitis C In Norwegian Prisons

Speaker: Joakim Hauge, Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Norway

#VP65: 30 Years Of HIV And Hepatitis Surveillance In People Who Inject Drugs Through The Unlinked Anonymous Monitoring Survey In England, Wales And Northern Ireland

Speaker: Sara Croxford, Public Health England, UK

#VP66: Modeling Hepatitis C Elimination Among People Who Inject Drugs Along The Us-Mexico Border: Is Microelimination Possible?

Speaker: Lara Marquez, University of California San Diego, USA

#VP67: Rapid Decline In The Population Prevalence Of Chronic HCV Among People Who Inject Drugs Associated With Scale-Up Of Direct-Acting Antiviral Therapy In Scotland: Real-World Data

Speaker: Norah Palmateer, Glasgow Caledonian University, UK

#VP68: The Civil Society Monitoring Of Progress In Hepatitis C Response For People Who Inject Drugs Related To The WHO 2030 Elimination Goals In 35 European Countries

Speaker: Mojca Maticic, University Medical Centre Ljubljana, Slovenia

#VP69: Prevalence Estimation Of HCV Among People Who Inject Drugs In Belgium Through Respondent Driven Sampling, Capture-Recapture And Multiplier Method

Speaker: Els Plettinckx & Luk Van Baelen, Sciensano, Belgium

#VP70: Homelessness, Unstable Housing And Risk Of HIV And Hepatitis C Virus Acquisition Among People Who Inject Drugs – A Systematic Review And Meta-Analysis

Speaker: Jack Stone, University of Bristol, UK

#VP71: Trends In Time To Treatment Initiation Among People Diagnosed With Hepatitis C In A Network Of Australian Clinical Services Between 2015-2019

Speaker: Michael Traegar, Burnet Institute, Australia

#VP72: Estimating Trends In Hepatitis C Incidence Among Individuals Attending Primary Care Clinics That Specialise In The Care Of People Who Inject Drugs In Australia Between 2009 And 2019

Speaker: Anna Wilkinson, Burnet Institute, Australia

#VP73: HIV And HCV Prevalence Among Registered PWID/PWUD With Diverse Poly-Drug Use Patterns At Fourteen AHRN Clinics In Areas Of High Burden Of Substance Use In Myanmar

Speaker: Khine Wut Yee Kyaw, Asian Harm Reduction Network, Myanmar

#PO46: Progress Towards Elimination Of Hepatitis C Among People Who Inject Drugs In Norway

Speaker: Knut Boe Kielland, Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Norway

#PO47: Effect Of Illicit Drugs Consumption Measured By Hair Analysis On Adherence And Efficacy Of Ravidasvir Plus Sofosbuvir In Asian Adults With Chronic HCV

Speaker: Laurent Brachet, DNDI, Switzerland

#PO48: A Multicentre Interventional Study To Assess Blood-Borne Viral Infections In Belgian Prisons

Speaker: Dana Busschots, Hasslet University, Belgium

#PO49: Hepatitis C Incidences And Risk Behaviors Among People Who Inject Drugs Accessing Harm-Reduction Services In Mombasa – Kenya

Speaker: Alfred Karisa, Reach Out Centre Trust, Kenya

#PO50: Hepatitis C Among People In Prison With Drug Injection History: Prevalence And Interventions In European Prisons

Speaker: Linda Montanari, EMCDDA, Portugal

#PO51: An Evaluation Of Hepatitis C Virus (HCV) Screening In Infants Born To Positive Mothers

Speaker: Angela Morris, Dalhousie Medicine New Brunswick, Canada

#PO52: A Network Of People Who Inject Drugs Successfully Produced A State Wide Authenticated HCV Prevalence Data Among PWIDs And Their Spouses. The Only State Data Ever Produced In Manipur, India

Speaker: Pramod Ningombam, Community Network For Empowerment (CONE), India

#PO53: Striving Toward The Cure For All: An Equity Assessment Of A Hepatitis C Elimination Program

Speaker: KayLynn Gesner, Oregon Health & Science University, USA

#PO54: Are Harm Reduction Projects For People Who Inject Drugs In Ukraine Improving HIV And HCV Prevention And Treatment Outcomes?

Speaker: Jack Stone, University of Bristol, UK

#PO55: Estimating The Number Of People In Prisons With Lifetime Injection Drug Use In Seven European Countries

Speaker: Vana Sypsa, University of Athens, Greece

#PO56: The Elimination Of Hepatitis C Infection Among People Who Inject Drugs From All Public Hospitals In Madrid

Speaker: Jeffrey V. Lazarus, University of Barcelona, Spain

#VP74: Hepatitis C Reinfection By Treatment Pathway Among People Who Inject Drugs In Tayside, Scotland

Speaker: Madeleine Caven, University of Dundee, UK

#VP75: Long-Term Evaluation Of HCV Re-Infection Rates Among Inner City Vulnerable Populations

Speaker: Brian Conway, Vancouver Infectious Diseases Centre, Canada

#VP76: High Rates Of HCV Reinfection And Retreatment In A Cohort Of PWID With HCV Cure: 3.5 Year Follow Up Data From The Anchor Cohort

Speaker: Sarah Kattakuzhy, Institute of Human Virology at the University of Maryland, USA

#VP77: Hepatitis C Treatment And Reinfection Surveillance Among People Who Inject Drugs In A Low-Threshold Program In Oslo, Norway

Speaker: Håvard Midgard, Akershus University Hospital, Norway

#VP79: HCV Reinfection Is Common In People Entering Prisons In Catalonia, Spain (Re-HCV Study)

Speaker: Veronica Saludes, ermans Trias i Pujol University Hospital and Research Institute (IGTP), Spain

#VP80: Reinfection Following Successful Direct-Acting Antiviral Therapy For HCV Infection Among People Attending An Inner-City Community Health Centre In Victoria, Canada

Speaker: Marion Selfridge, Cool Aid Community Health Center, Canada

#VP81: Population-Level Estimates Of Detected And Undetected Hepatitis C Reinfection Following The Early Scale-Up Of HCV DAA Treatment Among People Who Inject Drugs In Scotland

Speaker: Alan Yeung, Glasgow Caledonian University, UK

#PO57: Real-World Effectiveness Of Retreatment For Reinfection And Virological Failure Among People Who Inject Drugs In The Reach-C Cohort

Speaker: Joanne Carson, The Kirby Institute, UNSW Sydney, Australia

#PO58: Hepatitis C Reinfection In The Direct-Acting Antiviral Era: A Scoping Review

Speaker: Amy McEwan, Glasgow Caledonian University, UK

#VP82: HCV Diversity And Treatment Outcomes Following Direct-Acting Antiviral (DAA) Therapy In Benin

Speaker: Lucrece Ahovegbe, Mbarara University of Science and Technology, Uganda

#VP83: Hepatitis C Screening, Diagnosis, And Treatment Scale-Up Among People Who Use Drugs: Micro-Elimination In An Iranian City

Speaker: Maryam Alavi, The Kirby Institute, UNSW Sydney, Australia

#VP84: Impact Of Direct-Acting Antiviral Treatment On Mortality Related To Extrahepatic Manifestations: Findings From A Large Population-Based Cohort In British Columbia, Canada

Speaker: Dahn Jeong, University of British Columbia, Canada

#VP85: Removing Prescriber Restrictions For Opioid Agonist Therapy Can Facilitate Direct-Acting Antivirals Scale-Up In People With Opioid Use Disorders: Results From The ANRS Fantasio Project

Speaker: Fabienne Marcellin, French National Institute for Health and Medical Research (INSERM), France

#VP86: Real-World Outcomes In Patients With Chronic Hepatitis C Virus Infection And Substance Abuse Disorders Treated With Glecaprevir/Pibrentasvir For 8 Weeks: A Pooled Analysis Of Multinational Post-Marketing Observational Studies

Speaker: Guiliano Rizzardini, 1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Italy

##VP141: Real-World Outcomes In Patients With Chronic Hepatitis C Virus Infection And Substance Abuse Disorders Treated With Glecaprevir/Pibrentasvir For 8 Weeks: A Pooled Analysis Of Multinational Post-Marketing Observational Studies

Speaker: Juliette Foucher, Centre hospitalier Universitaire Bordeaux, France

#PO59: Does SVR After Direct Acting Antiviral (DAA) Therapy Affect The Quality Of Life (QoL) Of Patients With Chronic Hepatitis C (CHC) And A History Of Drug Use?

Speaker: Pinelopi Antonakaki, University of Athens, General Hospital of Athens “Hippocratio”, Greece

#PO60: Future Destinations And Social Inclusion: How People Cured Of Hepatitis C (HCV) Using Direct-Acting Antiviral Drugs Progress In A New HCV-Free World. A Scoping Review

Speaker: Sarah Donaldson, University of Dundee & NHS Tayside, UK

#PO62: Improving Quality Of Life Associated With HCV Cure And MOUD In Opioid Use Disorder Patients Receiving HCV Treatment

Speaker: Max Sparderna, University of Maryland School of Medicine, USA

#PO63: Efficacy Of Direct-Acting Antivirals(DAA’s) For Chronic Hepatitis C Virus Infection In People Who Receive Opioid Substitution Therapy (OST) Or Inject Drugs (PWID) In Central Greece

Speaker: Ioannis Xynotroulas, General Hospital of Lamia, Greece

#VP87: Seroprevalence And Risk Factors Of Exposure To Sars-Cov-2 Among People Who Use Drugs In Tehran, Iran

Speaker: Maryam Alavi, The Kirby Institute, UNSW Sydney, Australia

#VP88: Overdose Response In The Era Of COVID-19 And Beyond: How To Spot Someone So They Never Have To Use Alone

Speaker: Matt Bonn, Canadian Association of People Who Use Drugs & Canadian Students for Sensible Drug Policy

#VP89: High Sars-COV-2 Antibody Prevalence But No Severe Course Of COVID-19 Disease Among People Who Use Drugs In Opioid Agonist Treatment

Speaker: Philip Bruggmann, Arud Zentrum für Suchtmedizin, Switzerland 

#VP90: The Impact Of COVID-19 Pandemic On HCV Cascade Of Care In Vulnerable Populations In Slovenia: Results Of A National Study

Speaker: Jasna Cernosa, Clinic for Infectious Diseases and Febrile Illnesses, Slovenia

#VP92: “Grasping The Strings Of Balloons”: Kirketon Road Centre’s Group Counselling Model Of Care To Improve Well-Being During COVID And Beyond

Speaker: Julie Dubuc, Kirketon Road Centre, Australia

#VP93: Health Literacy And Changes In Pattern Of Drug Use Among Participants At The Stockholm Needle Exchange Program During The Covid-19 Pandemic

Speaker: Elin Holmen, Karolinska Institutet, Sweden

#VP94: “It’s Not What You Know, It’s Who You Know”: The Role Of Social Capital For People Receiving Opioid Agonist Treatment Amid COVID-19 Restrictions

Speaker: Lise Lafferty, Centre for Social Research in Health, UNSW Sydney, Australia

#VP95: Factors Influencing COVID-19 Vaccination Acceptability In Three Canadian Federal Prisons: A Qualitative Analysis Of Incarcerated People’s Perspectives

Speaker: David Lessard, MUHC, Canada

#VP96: Emerging Characteristics Of Drug Overdose Decedents During The COVID-19 Pandemic: A Statewide Analysis Leveraging Linked Databases

Speaker: Alexandria Macmadu, Brown University School of Public Health, USA

#VP97: Determinants Of Psychological Distress During The COVID-19 Pandemic Among People Who Use Drugs In Montreal, Canada

Speaker: Iuliia Makarenko, McGill University, Canada

#VP98: Trends In Social Injecting Behaviors And Hepatitis C Among People Who Inject Drugs In The San Diego Border Region As A Result Of The COVID-19 Pandemic: A Descriptive Analysis

Speaker: Lara Marquez, University of California San Diego, USA

#VP99: The COVID-19 Pandemic And People Who Inject Drugs In Montreal: A Rapid Assessment Study

Speaker: Nanor Minoyan, CRCHUM/ Université de Montréa, Canada

#VP100: Harm Reduction In The Time Of COVID: Integrated And Community-Led Services

Speaker: Sam Shirley-Bevan, Harm Reduction International, UK

#VP101: Facilitators And Barriers To Accessing Harm Reduction Services In A Rural State During COVID-19

Speaker: Kinna Thakarar, Maine Medical Center, USA

#VP102: Assessing The Impact Of COVID-19 And Associated Control Measures On Interventions To Prevent Blood-Borne Viruses Among People Who Inject Drugs In Scotland

Speaker: Kirsten Trayner, Glasgow Caledonian University/Public Health Scotland, UK

#VP103: Strategic Co-Localization Of HCV Testing With COVID-19 Vaccination To Enhance Engagement Among Priority Populations

Speaker: Aaron Vanderhoff, Viral Hepatitis Care Network (VIRCAN), Canada 

#VP104: HCV Testing And Treatment At Syringe Exchange Program In New York City During COVID-19

Speaker: Jeffrey Weiss, Icahn School of Medicine at Mount Sinai, USA

#PO64: Adherence To Addiction Centers During The COVID-19 Pandemic Of Individuals With Substance Use Disorders Is Low, Making Hepatitis C Screening And Treatment Difficult

Speaker: Cristina Marcos-Fosch, Vall Hebron Hospital, Spain

#PO65: Impact Of The COVID-19 Pandemic On Hepatitis C Virus Screening In Drug Treatment Settings In England: An 18-Month Analysis Between Sept19-Feb21

Speaker: Shayon Salehi, Gilead Sciences, UK

#PO66: The Impact Of The COVID-19 Pandemic On Harm Reduction Services In Addiction Centres And On The DAA Treatment Initiated In The Balearic Islands, Spain: Preliminary Results From A Novel Hepatitis C Elimination Programme

Speaker: Jeffrey V. Lazarus, University of Barcelona, Spain

#PO67: High Rates Of Suicidal Ideation, Prior Suicide Attempt And Intentional Overdose In People With OUD

Speaker: Elana Rosenthal, University of Maryland School of Medicine; DC Partnership for HIV/AIDS Progress Hepatitis C, USA

#PO68: Compliance And Access Of IVDU/ Hepatological Patients During The COVID-19 Pandemic In Greece

Speaker: Theofani Karaoulani, General Hospital of Lemnos, Greece

#PO69: Securing Safe Supply During COVID-19 And Beyond: Scoping Review And Knowledge Mobilization

Speaker: Matt Bonn, Canadian Association of People Who Use Drugs & Canadian Students for Sensible Drug Policy

#PO70: Benefits Of Take-Home Doses Among Patients Receiving Methadone Maintenance Treatment In Kachin State, Myanmar: A Hopeful Prospect Amid COVID-19 Pandemic And Beyond

Speaker: Me Me Thaw, Medecins Du Monde (France) – Myanmar Mission, France

#PO71: Adapting Recruitment Strategies In Substance Use Research During The COVID-19 Pandemic

Speaker: Isabelle Boisvert, Centre de recherche du CHUM, Canada

#PO72: Incorporating Telemedicine Into An Urban Hepatitis C Program During COVID-19

Speaker: Farah Riazi, Icahn School of Medicine At Mount Sinai, USA

#VP105: Increased Hepatitis C Screening And Diagnosis After Transfer Of Health Care Responsibility To Public Health System In British Columbia Correctional Centres

Speaker: Sofia Bartlett, BC Centre for Disease Control, Canada

#VP106: Housing Is Healthcare: HCV Treatment Outcomes For Individuals Experiencing Homelessness And Unstable Housing In Boston 

Speaker: Marguerite Beiser, Boston Health Care for the Homeless Program, USA

#VP107: Reducing Health Workers’ Stigmatising Attitudes Towards People Who Inject Drugs And People Living With HIV Via Micro-Learning Interventions

Speaker: Timothy Broady, Centre For Social Research In Health, UNSW Sydney, Australia

#VP108: Testing Persons In Prison For Hepatitis C Virus: A Service Improvement Project In Tayside, Scotland

Speaker: Christopher Byrne, University of Dundee, Scotland

#VP109: PIVOT: A ‘One Stop Shop’ Model Of Care To Test And Treat Hepatitis C In Custody

Speaker: Amanda Cochrane, JH&FMHN, Australia

#VP110: Blood Borne Virus (BBV) Testing In Prisons: Best Practice Toolkit For Reception Based Pathways

Speaker: Kate Dorrington, Gilead Sciences, UK

#VP111: Hepatitis C Elimination During A Global Pandemic: Resilience In Action

Speaker: Shelley Facente, Facente Consulting, USA

#VP112: Working To Eliminate Hepatitis C (HCV) In West Virginia (WV)

Speaker: Judith Feinberg, West Virginia University, USA

#VP113: Evaluation Of A Peer-And-Nurse-Led Primary Health Care And Hepatitis C Testing/Treatment Model Within A Peer-Based Needle And Syringe Program

Speaker: Brett Hadlow, Kirketon Road Centre, Australia & Tony McNaughton, NSW Users and AIDS Association, Australia

#VP114: Dorset ‘Pop Up’ Hepatitis C (HCV) Clinics – Reaching The Unreachable, Engaging The Disengaged

Speaker: Louise Hansford, Inclusion, UK

#VP117: Diagnosing And Treating Blood Borne Viruses (BBV) In 47 English Prisons Through Reception-Based Testing

Speaker: Andy Jones, Gilead Sciences, UK

#VP118: Program Costs Of A Co-Located Hepatitis C Treatment Intervention At A Syringe Service Program In New York City

Speaker: Shashi Kapadia, Weill Cornell Medicine, USA

#VP119: Scaling Up Hepatitis C Treatment Within The Prison Setting: The Role Of Social Capital

Speaker: Lise Lafferty, Centre For Social Research In Health, UNSW Sydney, Australia

#VP120: Insights Into The Drivers Of Variations In HIV Epidemic Patterns Among People Who Inject Drugs In Pakistan

Speaker: Aaron Lim, University of Bristol, UK

#VP121: Cedar Project HCV Blanket Program: Hepatitis C-Free Narratives Among Indigenous People Who Use (D) Drugs In British Columbia, Canada

Speaker: April Mazzuca, University of British Columbia, Canada

#VP122: Missing Piece Of The Puzzle: Bridging The Gap And Bringing Hepatitis C Testing And Treatment To Community Corrections For People Who Inject Drugs

Speaker: Winnie Nguyen, Hepatitis QLD, Australia

#VP123: HCV Blitzing In Corrections With Just A Fingerstick

Speaker: Mim O’Flynn, Kombi Clinic, Australia

#VP124: Do We Test-And-Treat Our HCV Patients In The Same Way? Time From Diagnosis To Treatment Among People Injecting Drugs Versus General Population

Speaker: Joss O’Loan, Kombi Clinic, Australia

#VP125: Quantifying Nurses Contribution To HCV Care Milestones: Findings From An Integrated Primary Healthcare Setting For Marginalised People

Speaker: Rosie Gilliver, Kirketon Road Centre, Australia

#VP126: “I’ve No Money, I’m About To Be Evicted”: Characteristics Of Clients And Utlity Of Receiving Financial Support For Direct Acting Antiviral Therapy Prescriptions

Speaker: Edmund Silins, Kirketon Road Centre, Australia

#VP127: A Costing Analysis Of A State-Wide, Nurse-Led Hepatitis C Treatment Model In Prison

Speaker: Nick Scott, Burnet Institute, Australia

#VP128: Development Of A Successful Telehealth Model Of Comprehensive Care And Provider Training For Hepatitis C And Opioid Use Disorder In A High Burden Region

Speaker: Terry Kemp-Knick, University of Virginia School of Medicine, USA

#VP129: Health Related Quality Of Life Of Patients In Opioid Substitution Therapy At The Beginning Of Hepatitis C Treatment – Data From The German Hepatitis C-Registry (DHC-R)

Speaker: Michael Specka, University Hospital, University of Duisburg-Essen, Germany

#VP130: A Community-Based Program To Increases Diagnosis And Treatment For HCV Infection Among High-Risk People Who Inject Drugs In Thessaloniki, Greece (Alexandros Program)

Speaker: Vana Sypsa, University of Athens, Greece

#VP131: Peer-Led Approach To Hepatitis-C Treatment In Kachin State, Myanmar

Speaker: Minn Thit Aung, Medecins Du Monde (France) – Myanmar Mission, France

#VP132: Multi-Stakeholder Partnership To Eliminate Hepatitis C Virus (HCV) In 47 English Prisons

Speaker: Philip Troke, Gilead Sciences, UK

#VP133: Hepatitis C Prevalence And Treatment Uptake At Opioid Agonist Therapy Clinics In Ontario, Canada

Speaker: Brett Wolfson-Stofko, Viral Hepatitis Care Network (VIRCAN) – University Health Network, Canada

#VP134: The Learning Community Model For Integrating Hepatitis C Services Into Opioid Treatment Programs

Speaker: Kelly Reinhardt, University Of Missouri Kansas City, USA

#PO73: Access Barriers To Diagnosis And Treatment Of Hepatitis C For PWID In Pereira (Colombia): The Role Of Community Based Organizations

Speaker: Hugo Armando Castro, Corporacion Temeride, Colombia

#PO74: Pathways To Hepatitis C & HIV Care In Correctional Settings: Partnering With People In Prison To Co-Create Policies And Guidelines

Speaker: Sofia Bartlett, BC Centre for Disease Control, Canada

#PO75: Hepatitis Bus – A Norwegian Outreach Project

Speaker: Ronny Bjørnestad, Prolar Nett, Norway

#PO76: The HepCare Project Of The Swiss Hepatitis Strategy: With GP Empowerment Towards Hepatitis C Elimination

Speaker: Philip Bruggmann, Arud Zentrum für Suchtmedizin, Switzerland

#PO77: Getting Access To HCV Treatment Among People Who Inject Drugs In Malaysia, A Community Led

Speaker: Manis Chen, Positive Malaysian Treatment and Advocacy Group, Malaysia

#PO78: Collaborative Care: Hepatitis C Treatment In A Primary Care Setting

Speaker: Katherine Davidson, NHS Lothian, UK

#PO79: Promoting The Hep C Community Navigation Program Model: Effectiveness Of The Dissemination Strategy

Speaker: Diana Diaz Munoz, Department Of Health & Mental Hygiene, USA

#PO80: Baseline Capability For Hepatitis Test And Treatment In Drug Treatment Clinics In The Region Of Southern Denmark- A Pre Elimination Intervention Assessment

Speaker: Sandra Drose, University of Southern Denmark, Denmark

#PO81: The Big Blue Bus In Birmingham (UK)

Speaker: Lisa Ellis, University Hospital Birmingham, UK

#PO82: Evaluation Of A Peer Support Model Focused On Improving Access To HCV Care In Community Settings – ‘Peers Assisting Treatment Of Hepatitis C’ (PATH)

Speaker: Imogen Elsum & Carolyn Weidner, Burnet Institute, Australia

#PO83: On-Site HCV Treatment For Patients Receiving Opioid Substitution Therapy (OST) In NJ

Speaker: James Fallon, Jihad Slim, Llc, USA

#PO84: The Hepatitis Engagement Program (HEP): Using A Patient-Informed Outreach Strategy To Increase Hepatitis C Screening And Treatment Engagement Among Adults In Their Primary Child-Bearing Years In Pre-Pandemic New Brunswick, Canada

Speaker: Kate Harland, Centre for Research, Education, and Clinical Care of At-Risk Populations (RECAP), Canada

#PO85: Peer Counseling On HCV And HBV In Darknet: Case From Saint Petersburg, Russia

Speaker: Aleksey Lakhov, Saint Petersburg Charitable Fund “Humanitarian Action”, Russia

#PO86: Linkage To Hepatitis C Treatment In Two Opioid Substitution Treatment Units

Speaker: Simon Larsson, Sahlgrenska University Hospital, Sweden

#PO87: The EC Nurse-Led Model Of Care And The Impact On Hepatitis C Testing Coverage In A Network Of High Caseload Primary Care Clinics In Victoria, Australia

Speaker: Chloe Layton, Burnet Institute, Australia

#PO88: Feasibility Of HCV Micro-Elimination In Two Harm Reduction Services In Milan

Speaker: Sara Mazzilli, Scuola Normale Superiore, Pisa, Italy

#PO89: Nurse-Initiated Screening For Hepatitis C Treatment In PWID: An Algorithm

Speaker: Heather McEwan, Portland Hotel Society, USA

#PO90: Access And Utilisation Of Reproductive, Maternal, Neonatal And Child Health Services Among Women Who Inject Drugs In Coastal Kenya: Findings From A Qualitative Study

Speaker: Rahab Njeri, Nairobi University, Kenya

#PO92: Screening For HCV In A Migrant Population In The Mobile Outreach Program Of Lisbon

Speaker: Claúdia  Pereira, Ares Do Pinhal, Portugal

#PO93: A Peer Led Partnership Achieves Whole SMS Service HCV Testing And Treatment

Speaker: Carrie Richardson, Hep C Trust, UK

#PO94: Building Bridges Over Troubled Waters: HCV Screening And Linkage To Care In The Age Of The Opioid Epidemic

Speaker: Marrie Sutton, Imagine Hope Inc, USA

#PO95: Integrated Collaborative Care To Address The Behavioral Health Needs Of People Living With HIV And Untreated HCV

Speaker: Megan Urry, New York-Presbyterian Hospital at Columbia University Irving Medical Center, USA

#PO96: A New Model Of Care For Hepatitis C Launched After 1 Year Of The Covid-19 Pandemic In The Balearic Islands: First Results

Speaker: Jeffrey V. Lazarus, University of Barcelona, Spain

#PO97: Effectiveness Of An HIV Care Model Integrated Into Addiction Care Based On Medication-Assisted Treatment For HIV-Positive People Who Use Drugs

Speaker: Jorge Valencia, Hospital Universitario Infanta Leonor, Spain

#PO98: Peer Harm Reduction In The Yard (PHRY) – A Pilot Peer Education Program In NSW Prisons 

Speaker: Thomas Wright, Justice Health and Forensic Mental Health Network, Australia

#VP136: Reduction In Hepatitis B Vaccine Uptake In Young People Who Inject Drugs and Recent Initiates In England, Wales and Northern Ireland, 2017 – 2018

Speaker: Jacquelyn Njoroge, Public Health England, UK

#VP137: How Can We Increase Influenza Vaccine Update Among People Who Inject Drugs?

Speaker: Olivia Price, National Drug and Alcohol Research Centre, Australia

#PO99: Association Between Hepatitis B and Syphilis Infection Among Adults Receiving Antiretroviral Therapy In Zambia

Speaker: Benson Hamooya, Mulungushi University School of Medicine and Health Sciences, Zambia

#PO100: Conducting Proper Hepatitis B Test Among Pregnant Women Accessing Health Care Services In Traditional Birth Attendants (TBAs) In Rural Community Of Nigeria

Speaker: Kayode Owoso, 360 Health Systems Diagnostics and Correction (360 HSDC), Nigeria

#PO101: High Accuracy Of Self-Collection Testing Of Hepatitis B Core Antibody On Serum Separator Cards

Speaker: Mariko Nakano, Molecular Testing Labs, USA